Skip to content

Advertisement

  • Research
  • Open Access

Dexmedetomidine ameliorates acute lung injury following orthotopic autologous liver transplantation in rats probably by inhibiting Toll-like receptor 4–nuclear factor kappa B signaling

†Contributed equally
Journal of Translational Medicine201513:190

https://doi.org/10.1186/s12967-015-0554-5

©  Chi et al. 2015

  • Received: 19 April 2015
  • Accepted: 1 June 2015
  • Published:

Abstract

Background

To investigate whether pretreatment with dexmedetomidine (Dex) has a protective effect against acute lung injury (ALI) in an orthotopic autologous liver transplantation (OALT) rat model and to explore the mechanisms responsible for the protective effect of Dex against lung injury.

Methods

Forty-eight rats underwent OALT and were randomly divided into six groups (n = 8 in each group) that received 10 µg/kg Dex, 50 µg/kg Dex, 50 µg/kg Dex + nonspecific α2-adrenergic receptor (AR) antagonist atipamezole, 50 µg/kg Dex + specific α2B/C-AR antagonist ARC-239, 50 µg/kg Dex + specific α2A-AR antagonist BRL-44408, or the same amount of normal saline. The sham rats (n = 8) underwent anesthesia induction, laparotomy, and separation of the portal vein without liver ischemia and reperfusion. Lung tissue sections were stained with hematoxylin and eosin (HE) to visualize the damage. The expression of Toll-like receptor 4 (TLR4) and the phospho-nuclear factor (NF)-κB p65 subunit as well as inflammatory cytokines was measured.

Results

Rats exhibited increased histological lung injury scores and pulmonary edema following OALT. Pretreatment with 50 μg/kg Dex attenuated OALT-induced lung injury in rats, probably by inhibiting the activation of the TLR4–NF-κB signaling pathway. The protective effect of Dex could be blocked by atipamezole or BRL-44408, but not by ARC-239, suggesting these effects of Dex were mediated, at least in part, by the α2A-AR.

Conclusions

Dex exerts protective effects against ALI following OALT, and this protection is associated with the suppression of TLR4–NF-κB signaling. Thus, pretreatment with Dex may be a useful method for reducing lung damage caused by liver transplantation.

Keywords

  • Liver transplantation
  • Acute lung injury
  • Toll-like receptor 4
  • Dexmedetomidine

Background

Acute lung injury (ALI) is a common complication following liver transplantation, with an incidence between 34.2 and 77.8% [1, 2]. ALI is a progressive, devastating disease characterized by bilateral lung infiltration, hypoxemia refractory to oxygen therapy, and decreased lung compliance. Patients who develop ALI may further develop acute respiratory distress syndrome (ARDS), which has become one of the major causes of death after liver transplantation [3, 4]. Therefore, treatment strategies to protect against ALI after liver transplantation have been studied.

Toll-like receptor 4 (TLR4) is a member of the TLR family that plays a key role in both innate and adaptive immune responses. Triggering of the TLR pathway leads to activation of nuclear factor kappa B (NF-κB) and subsequent regulation of immune and inflammatory genes/factors, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, and IL-8 [5–7]. Previous studies revealed increased expression of TLR4 in peripheral blood mononuclear cells and pro-inflammatory cytokines during the perioperative period of liver transplantation, indicating the involvement of TLR4 signaling in the development of ALI after liver transplantation [3, 8].

The alpha 2 adrenergic receptor (α2-AR) is a prototypical G protein-coupled receptor (GPCR). α2-AR mediates the physiological and pharmacological actions of catecholamines via G-proteins to a variety of effectors, including adenylyl cyclases and ion channels [9, 10]. The α2-AR subfamily includes three different subtypes (α2A, α2B, and α2C) in mammals, and they are found ubiquitously in vital organs and blood vessels [11, 12]. Dexmedetomidine (Dex) is a potent agonist for all three subtypes of human α2-ARs, having sedative, analgesic, and anti-sympathetic effects [11]. Dex has been shown to provide good perioperative hemodynamic stability and to have a protective effect on specific organs, including the heart, brain, and kidney, probably via decreasing cell apoptosis in a Bax/Bcl-2-related manner [13] and inhibiting pro-inflammatory cytokine release [14–16].

To date, few studies have examined the protective effects of Dex against perioperative ALI after liver transplantation. Our study aimed to investigate whether pretreatment with Dex resulted in a protective effect against ALI in an orthotopic autologous liver transplantation (OALT) rat model and to explore the underlying mechanisms of this protective effect.

Methods

Animals

Male Sprague–Dawley rats (aged 8–10 weeks, weighing 220–250 g) were purchased from the Medical Experimental Animal Center of Guangdong Province, China. The study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, 1985) [17] and was approved by the local Ethical Committee of the Third Affiliated Hospital, Sun Yat-Sen University.

Preparation of experimental animal models

The rats were kept under observation in a constant environment (room temperature 25–27°C) for 1 week prior to the start of the experiments. The OALT model was established in Sprague–Dawley rats as previously reported [18]. Briefly, under anesthesia, the falciform ligament of the liver of the rat was severed. The first hepatic portal was dissected, and the portal vein (PV) was liberated. The hepatic artery and biliary tract were liberated together based on their anatomic relationship. Vascular clamps were applied at the convergence of the inferior mesenteric, splenic veins, hepatic artery, supra hepatic vena cava (SVC), and inferior vena cava (IVC). The PV was punctured with a needle in preparation for reperfusion using pre-cooled Ringer lactate solution. Finally, the needle was extracted, and the PV, SVC, IVC, and hepatic artery were unclamped. All rats were sacrificed 8 h after liver reperfusion for collection of blood and lung samples.

Grouping and drug treatment

Forty-eight rats subjected to OALT were randomly divided into six groups (n = 8 in each group) that received 10 µg/kg Dex (group D1), 50 µg/kg Dex (group D2), 50 µg/kg Dex + nonspecific α2-AR antagonist atipamezole (group B1), 50 µg/kg Dex + specific α2B/C-AR antagonist ARC-239 (group B2), 50 µg/kg Dex + specific α2A-AR antagonist BRL-44408 (group B3), or the same amount of normal saline (model group or group M) [19]. The rats were intraperitoneally injected with Dex at different doses 30 min before OALT, and 500 µg/kg atipamezole, 1.5 mg/kg BRL-44408, or 50 µg/kg ARC-239 40 min before OALT, according to the group designations. The dose selection of antagonists was based on the antagonists’ affinity and dose–effect relationship with Dex. The sham rats (n = 8; the sham group or group S) underwent anesthesia induction, laparotomy, and separation of the portal vein without liver ischemia and reperfusion.

Histological analysis of lung tissues

Lung tissues were fixed, sectioned at 4 μm thickness, and stained with hematoxylin and eosin (HE). The sections were scored as previously reported, and the histological scoring parameters included edema of the alveoli, edema of the alveolar mesenchyme, intra-alveolar cell infiltration, alveolar hemorrhage, and atelectasis [18].

Lung wet-to-dry (W/D) weight ratio

The wet (W) and dry (D) weights (after drying in ventilated oven at 80°C for 24 h) of the right middle lung lobes were measured. The lung W/D weight ratio was calculated by dividing the wet weight by the dry weight.

Western blotting analysis of TLR4 expression

Protein samples were extracted from the lung tissues. Samples (20 μg protein) were loaded onto a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel and then transferred onto a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with 5% fat-free in Tris-buffered saline-Tween (TBS-T) blocking solution (containing 0.2% Tween-20, 20 mmol/L Tris–HCl, and 150 mmol/L NaCl, pH 7.14) at 37°C for 1 h, followed by incubation with primary antibody (1:1,000; Abcam, USA) at 37°C for 2 h. Membranes were washed with TBS solution containing 1% milk four times and then incubated at room temperature for 1 h with horseradish peroxidase (HRP)-conjugated secondary antibody (dilution 1:2,000, Santa Cruz Biotechnology, CA, USA). The bands on the membranes were visualized by an enhanced chemiluminescence (ECL) system. The density of each band was quantified by an image analyzer (Lab Works Software, CA, USA) and corrected by reference to the expression value for glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Immunofluorescent assay and laser scanning confocal microscopy (LSCM)

Paraffin-embedded sections of lung tissue were dewaxed and rehydrated. Antigen retrieval was performed by heating in citrate buffer (pH = 6.0). Then, the sections were treated with 3% hydrogen peroxide (H2O2) for 10 min and incubated with a primary rabbit phospho-NF-κB p65 antibody (Cell Signaling Technology, MA, USA) at a dilution of 1:100, overnight at 4°C. The sections were washed with phosphate-buffered saline (PBS) and then further incubated with a fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit secondary antibody at a dilution of 1:100 (Life Technologies, USA) for 2 h at room temperature in the dark. The sections were counterstained with 4,6-diamidino-2-phenylindole (DAPI) to visualize nuclei. Images were captured by LSCM (Zeiss LSM 510 META, Jena, Germany).

Enzyme-linked immunosorbent assay (ELISA)

The lung tissues were homogenized and centrifuged. The TNF-α and IL-1β levels in the lung tissues were measured using commercially available ELISA kits (Keygen Biotech, Nanjing, China), according to the instructions provided by the manufacturer.

Detection of myeloperoxidase (MPO) activity

MPO activity, an indicator of polymorphonuclea (PMN) infiltration, was determined as previously described [20]. MPO activity was defined as the quantity of enzyme that degraded 1 mmol H2O2 at 37°C, and it was expressed as U/g wet tissue.

Statistical analysis

All statistical analyses were performed using SPSS 13.0 (SPSS, Inc., IL, USA). Tests for normality and homogeneity of variances were performed. For normally distributed data, quantitative data are presented as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used to test for differences among the seven groups. A statistical difference was considered when the P value was less than 0.05.

Results

Histological findings

Results obtained from light microscopy in the sham group (group S) showed complete structural integrity, clear alveolar space, and normal alveolar septum. In contrast, extensive pulmonary destruction, including massive inflammatory cell infiltration, obvious pulmonary hemorrhage, marked thickening of alveolar septum, and significant increase in the proportion of lung parenchyma, was observed in the group M. The rats in group M showed a higher pathological score than those in group S (P < 0.01). Dex pretreatment effectively reduced inflammatory cell infiltration and inhibited thickening of alveoli septum in lung tissue, and this effect showed a dose–effect relationship. Rats pretreated with 10 µg/kg or 50 µg/kg Dex had lower pathological scores than rats in group M (P < 0.01). Interestingly, the protective effect of Dex could be blocked by the nonspecific α2-AR antagonist atipamezole or α2A-AR antagonist BRL-44408 (P < 0.01, group B1 or B3 vs. group D2) but not by the α2B/C-AR antagonist ARC-239 (P > 0.05, group B2 vs. group D2; Figures 1, 2a).
Figure 1
Figure 1

Pathological changes in lung tissue in each group. Images (magnification, ×200) of representative sections from rat lungs stained with hematoxylin and eosin after harvest from group S (a), group M (b), group D1 (c), group D2 (d), group B1 (e), group B2 (f), and group B3 (g).

Figure 2
Figure 2

Pathological scores of lung injury (a) and lung wet-to-dry (W/D) weight ratio (b) in each group. The data are expressed as mean ± standard deviation (SD) (n = 8). ▲ P < 0.01 vs. group S; ■ P < 0.01 vs. group M; ◆ P < 0.01 vs. group D2.

Lung W/D weight ratio

The lung W/D weight ratio was used as an index of water accumulation in the lung. The lung water content of the right middle lobes in rats increase significantly after OALT (P < 0.01, group M vs. group S). Pretreatment with 10 µg/kg or 50 µg/kg Dex remarkably reduced the water content of lung (P < 0.01, group D1 or D2 vs. group M). Treatment with atipamezole or BRL-44408, but not ARC-239, weakened the protective effect of Dex against pulmonary edema (P < 0.01, group B1 or B3 vs. group D2; Figure 2b).

Expression of TLR4 and phospho-NF-κB p65 subunit in lung tissues

The expression of TLR4 protein was measured by Western blotting. TLR4 protein expression was significantly enhanced in lung tissues following OALT (P < 0.01, group M vs. group S). Pretreatment with Dex at 50 µg/kg downregulated the expression of TLR4 protein (P < 0.01, group D2 vs. group M), and this effect was reversed by treatment with atipamezole or BRL-44408 (P < 0.05, group B1 or B3 vs. group D2), but not by ARC-239 (P > 0.05, group B2 vs. group D2; Figure 3).
Figure 3
Figure 3

The expression of TLR4 protein in lung tissues of different groups. a The levels of TLR4 protein were determined by Western blotting analysis. b Quantification of the Western blotting data and correction by reference to the value of GAPDH expression. The data are expressed as mean ± SD (n = 8). ▲ P < 0.01; △ P < 0.05 vs. group S; □ P < 0.05 vs. group M; ◇ P < 0.05 vs. group D2.

Cells stained positively for phospho-NF-κB were observed and counted under LSCM (magnification, 400×). The expression of the phospho-NF-κB p65 subunit was significantly increased in rats after OALT (P < 0.01, group M vs. group S), suggesting an increased transport of activated NF-κB complexes into the nucleus. Pretreatment with 10 µg/kg or 50 µg/kg Dex down-regulated the elevated phospho-NF-κB p65 subunit expression after OALT (P < 0.01, group D1 or D2 vs. group M), indicating that Dex pretreatment might inhibit the activation and nuclear transport of NF-κB proteins. The effect of Dex on the phospho-NF-κB p65 subunit was diminished by treatment with atipamezole or BRL-44408 (P < 0.05, group B1 or B3 vs. group D2), but not ARC-239 (P > 0.05, group B2 vs. group D2; Figures 4, 5).
Figure 4
Figure 4

The expression of the phospho-NF-κB p65 subunit in lung tissues of different groups was detected by immunofluorescence staining under laser scanning confocal microscopy (magnification, ×400). a Group S; b, group M; c, group D1; d, group D2; e, group B1; f, group B2; and g, Group B3. Cells positive for phospho-NF-κB p65 were stained green, with the sections counterstained with 4,6-diamidino-2-phenylindole (DAPI) to visualize nuclei.

Figure 5
Figure 5

The proportion of phospho-NF-κB subunit p65 positive cells in lung tissues of different groups. The cells were counted under laser scanning confocal microscopy (magnification, ×400). The data are expressed as mean ± standard deviation (SD) (n = 8). ▲ P < 0.01; △ P < 0.05 vs. group S; □ P < 0.05 vs. group M; ◇ P < 0.05 vs. group D2.

TNF-α and IL-1β concentrations and MPO activity in lung tissues

Production of pro-inflammatory factors in the lung is considered indicative of the severity of lung injury [21]. To evaluate the production of pro-inflammatory factors following OALT, TNF-α and IL-1β levels were examined by ELISA. The TNF-α and IL-1β levels in lung tissues were significantly higher in group M than in group S (P < 0.05). Pretreatment with Dex appeared to have a stronger effect on reducing the levels of TNF-α and IL-1β (P < 0.05, group D1 or D2 vs. group M). However, these effects of Dex could be almost completely blocked by treatment with atipamezole or BRL-44408 (P < 0.05, group B1 or B3 vs. group D2), but not by ARC-239 (P > 0.05, group B2 vs. group D2). The MPO activity in lung tissues was consistent with TNF-α and IL-1β levels and showed a similar trend among the groups (Figure 6).
Figure 6
Figure 6

The concentrations of TNF-α (a) and IL-1β (b) and MPO activity (c) in lung tissues of different groups. The data are expressed as mean ± SD (n = 8). ▲ P < 0.01; △ P < 0.05 vs. group S; ■ P < 0.01 vs. group M; ◆ P < 0.01 vs. group D2.

Discussion

This study investigated whether pretreatment with Dex has a protective effect against ALI in an OALT rat model. We found that Dex exerts protective effects against ALI following OALT, and this protection was mediated, at least in part, by the α2A-AR and was associated with the suppression of TLR4–NF-κB signaling.

In this study, we successfully established an OALT model according to a method used in previous studies [22]. This liver model can exactly imitate human pathophysiologic conditions of liver transplantation. Pathological changes in lung tissues following OALT included extensive pulmonary destruction such as massive inflammatory cell infiltration, obvious pulmonary hemorrhage, and marked alveolar septum thickening. Moreover, the pulmonary edema evaluated according to the W/D weight ratio was markedly increased after OALT as well. These results, taken together, provide definitive evidence for ALI in the OALT model. We chose 8 h after transplantation as the observation point based on our previous research, which indicated that rats present the most serious damage to the lung at 8 h after liver transplantation.

Several triggering conditions, including hemorrhagic shock, endotoxin, trauma, burn injury, and ischemia–reperfusion, contribute to ALI and exaggerate the inflammatory process of ALI [23–25]. NF-κB is an important nuclear transcription factor that upon activation, transfers into the nucleus, amplifying inflammatory responses by promoting production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8 [26, 27]. TLR4 plays an important role in the pathogenesis of ALI via activation of NF-κB signaling [7, 8, 24]. In a lipopolysaccharide (LPS)-induced ALI model, the gene expression level of pulmonary cytokines, such as TNF-α, IL-1β, and IL-6, is significantly increased in wild-type mice compared with TLR4-deficient mice [28]. A study by Lorenz et al. found that TLR4-deficient murine macrophage cells are nonresponsive to stimulation by endotoxically active LPS of gram-negative bacteria, even under a high concentration [29]. Although direct blockade of TLR4 may potentially serve as an effective therapeutic strategy for acute pulmonary inflammation and ALI [30, 31], blockade of TLR4 must be applied with caution, because TLR4 blockade is not beneficial for patients with sepsis [32]. Our findings revealed that the TLR4–NF-κB signaling pathway is involved in the pathogenesis of ALI after liver transplantation, as evidenced by increased levels of TLR4 and phospho-NF-κB p65 subunit protein as well as proinflammatory cytokines TNF-α and IL-1β in the injured lung.

Dex has been reported to exert protective effects in various pulmonary conditions [15, 33]. Dex may directly suppress the immune response by modulating TLR4 expression, which results in inhibition of inflammatory cytokine production. A study by Want et al. demonstrated that Dex might exert its protective effects against hydrogen sulfide-induced ALI through down-regulation of matrix metalloproteinase (MMP)-2 and MMP-9 expression [34]. It was also reported that pretreatment with Dex significantly reduces the lung injury caused by ischemia–reperfusion injury [15]. Our study found that pretreatment with Dex could cause a significant decrease in lung pathological scores and the lung W/D weight ratio, suggesting a protective effect of Dex on lung tissue. NF-κB activation was attenuated in rats treated with Dex, which was consistent with the changes in the expression of TLR4 as well as pro-inflammatory cytokines TNF-α and IL-1β in the lung tissue following OALT. Yang et al. [33] reported that Dex at the dose of 5.0 µg/kg per h significantly attenuated the effects of ventilator-induced lung injury, which was mediated by the α2-AR.

Human and rat kidneys are reported to contain all three types of α2-ARs [35]. In this study, we used different α2-AR antagonists to elucidate the contribution of these α2-AR subtypes to the effects of Dex. Interestingly, the protective effects of Dex could be blocked by the nonspecific α2-AR antagonist atipamezole or α2A-AR antagonist BRL-44408, but not by the α2B-AR antagonist ARC-239, suggesting these effects of Dex were mediated, at least in part, by the α2A-AR. Our results are consistent with previous findings that Dex provides potent neuroprotection mediated via the α2A-AR subtype in a model of perinatal excitotoxic brain injury [36]. The exact mechanism by which Dex exerts its protective effects via the α2A-AR requires further investigation.

Conclusions

Dex exerts protective effects against ALI following OALT, and this protection is associated with the suppression of TLR4–NF-κB signaling, which may explain the inhibitory effect of Dex on the production of pro-inflammatory factors TNF-α and IL-1β. These effects of Dex were mediated by the α2A-AR. Thus, pretreatment with Dex may be a useful method for reducing the lung damage caused by liver transplantation.

Notes

Declarations

Author’s contributions

XC and XW contributed equally to this study. Conceived and designed the experiments: XC and JC. Performed the experiments: XW, WG, JG and XL. Analyzed the data: XY and YW. Contributed reagents/materials/analysis tools: JC and CL. Wrote the paper: XC. All authors read and approved the final manuscript. Address correspondence to Xinjin Chi: Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China. chixinjin@yeah.net; and co-correspondence to Jun Cai: Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China. cj_gz@tom.com.

Acknowledgements

The study was supported by the Natural Science Foundation of China (No. 81471892), the Natural Science Foundation of Guangdong Province, China (No. 2014A030313199), the Science and Technology Project Foundation of Guangdong Province, China (No. 2008B030301053; No. 2013B021800181) and the Outstanding Young Teacher Training Program of Sun Yat-sen University, China (No. 14ykpy24).

Compliance with ethical guidelines

Competing interests The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Anesthesiology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510630, China
(2)
Department of Anesthesiology, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, China
(3)
Department of Anesthesiology, First Affiliated Hospital, University of South China, Hengyang, Hunan, 421001, China
(4)
Department of Thyroid and Breast Surgery, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510630, China

References

  1. Hong SK, Hwang S, Lee SG, Lee LS, Ahn CS, Kim KH et al (2006) Pulmonary complications following adult liver transplantation. Transplant Proc 38:2979–2981PubMedView ArticleGoogle Scholar
  2. Yao W, Luo G, Zhu G, Chi X, Zhang A, Xia Z et al (2014) Propofol activation of the Nrf2 pathway is associated with amelioration of acute lung injury in a rat liver transplantation model. Oxid Med Cell Longev 2014:258567Google Scholar
  3. Chi XJ, Cai J, Luo CF, Cheng N, Hei ZQ, Li SR et al (2009) Relationship between the expression of Toll-like receptor 2 and 4 in mononuclear cells and postoperative acute lung injury in orthotopic liver transplantation. Chin Med J (Engl) 122:895–899Google Scholar
  4. Feltracco P, Carollo C, Barbieri S, Pettenuzzo T, Ori C (2013) Early respiratory complications after liver transplantation. World J Gastroenterol 19:9271–9281PubMed CentralPubMedView ArticleGoogle Scholar
  5. Yang Z, Deng Y, Su D, Tian J, Gao Y, He Z et al (2013) TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury. Lab Invest 93:792–800PubMedView ArticleGoogle Scholar
  6. Sabroe I, Parker LC, Dower SK, Whyte MK (2008) The role of TLR activation in inflammation. J Pathol 214:126–135PubMedView ArticleGoogle Scholar
  7. O’Neill LA (2003) Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 3:396–403PubMedView ArticleGoogle Scholar
  8. Hei Z, Chi X, Cheng N, Luo G, Li S (2010) Upregulation of TLR2/4 expression in mononuclear cells in postoperative systemic inflammatory response syndrome after liver transplantation. Mediators Inflamm 2010:519589PubMed CentralPubMedView ArticleGoogle Scholar
  9. Mantz J, Josserand J, Hamada S (2011) Dexmedetomidine: new insights. Eur J Anaesthesiol 28:3–6PubMedView ArticleGoogle Scholar
  10. Olli-Lähdesmäki T, Kallio J, Scheinin M (1999) Receptor subtype-induced targeting and subtype-specific internalization of human alpha(2)-adrenoceptors in PC12 cells. J Neurosci 19:9281–9288PubMedGoogle Scholar
  11. Brede M, Philipp M, Knaus A, Muthig V, Hein L (2004) Alpha2-adrenergic receptor subtypes—novel functions uncovered in gene-targeted mouse models. Biol Cell 96:343–348PubMedGoogle Scholar
  12. Malmberg AB, Hedley LR, Jasper JR, Hunter JC, Basbaum AI (2001) Contribution of alpha(2) receptor subtypes to nerve injury-induced pain and its regulation by dexmedetomidine. Br J Pharmacol 132:1827–1836PubMed CentralPubMedView ArticleGoogle Scholar
  13. Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E et al (2003) The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-d-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 96:524–531PubMedGoogle Scholar
  14. Sugita S, Okabe T, Sakamoto A (2013) Continuous infusion of dexmedetomidine improves renal ischemia-reperfusion injury in rat kidney. J Nippon Med Sch 80:131–139PubMedView ArticleGoogle Scholar
  15. Shen J, Fu G, Jiang L, Xu J, Li L, Fu G (2013) Effect of dexmedetomidine pretreatment on lung injury following intestinal ischemia–reperfusion. Exp Ther Med 6:1359–1364PubMed CentralPubMedGoogle Scholar
  16. Curtis FG, Vianna PT, Viero RM, Fiorio PM, Silva LM, Braz JR (2011) Dexmedetomidine and S(+)-ketamine in ischemia and reperfusion injury in the rat kidney. Acta Cir Bras 26:202–206PubMedView ArticleGoogle Scholar
  17. U.S. Office of Science and Technology Policy (1985) Technology, Laboratory animal welfare; U.S. government principles for the utilization and care of vertebrate animals used in testing, research and training; notice. Fed Regist 50:20864–5Google Scholar
  18. Chi X, Zhang A, Luo G, Xia H, Zhu G, Hei Z et al (2013) Knockdown of myeloid differentiation protein-2 reduces acute lung injury following orthotopic autologous liver transplantation in a rat model. Pulm Pharmacol Ther 26:380–387PubMedView ArticleGoogle Scholar
  19. Hanci V, Yurdakan G, Yurtlu S, Turan IÖ, Sipahi EY (2012) Protective effect of dexmedetomidine in a rat model of alpha-naphthylthiourea-induced acute lung injury. J Surg Res 178:424–430PubMedView ArticleGoogle Scholar
  20. Mullane KM, Kraemer R, Smith B (1985) Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:157–167PubMedView ArticleGoogle Scholar
  21. Deng JC, Standiford TJ (2011) Growth factors and cytokines in acute lung injury. Compr Physiol 1(1):81–104PubMedGoogle Scholar
  22. Ma K, Dai XW, Wang RP, Pu XM (1998) Intra inferior vena cava shunt: a new hamster model of orthotopic hepatic transplantation. J China Med Univ 27:356–358Google Scholar
  23. von Dossow-Hanfstingl V (2012) Advances in therapy for acute lung injury. Anesthesiol Clin 30:629–639View ArticleGoogle Scholar
  24. Hu R, Xu H, Jiang H, Zhang Y, Sun Y (2013) The role of TLR4 in the pathogenesis of indirect acute lung injury. Front Biosci 18:1244–1255View ArticleGoogle Scholar
  25. Tolle LB, Standiford TJ (2013) Danger-associated molecular patterns (DAMPs) in acute lung injury. J Pathol 229:145–156PubMedView ArticleGoogle Scholar
  26. Zingarelli B, Piraino G, Hake PW, O’Connor M, Denenberg A, Fan H et al (2010) Peroxisome proliferator-activated receptor delta regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis. Am J Pathol 177:1834–1847PubMed CentralPubMedView ArticleGoogle Scholar
  27. Kaplan J, Nowell M, Chima R, Zingarelli B (2013) Pioglitazone reduces inflammation through inhibition of NF-kappaB in polymicrobial sepsis. Innate Immun 20:519–528PubMedView ArticleGoogle Scholar
  28. Baumgarten G, Knuefermann P, Wrigge H, Putensen C, Stapel H, Fink K et al (2006) Role of Toll-like receptor 4 for the pathogenesis of acute lung injury in Gram-negative sepsis. Eur J Anaesthesiol 23:1041–1048PubMedView ArticleGoogle Scholar
  29. Lorenz E, Patel DD, Hartung T, Schwartz DA (2002) Toll-like receptor 4 (TLR4)-deficient murine macrophage cell line as an in vitro assay system to show TLR4-independent signaling of Bacteroides fragilis lipopolysaccharide. Infect Immun 70:4892–4896PubMed CentralPubMedView ArticleGoogle Scholar
  30. Smith LS, Kajikawa O, Elson G, Wick M, Mongovin S, Kosco-Vilbois M et al (2008) Effect of Toll-like receptor 4 blockade on pulmonary inflammation caused by mechanical ventilation and bacterial endotoxin. Exp Lung Res 34:225–243PubMedView ArticleGoogle Scholar
  31. Leon CG, Tory R, Jia J, Sivak O, Wasan KM (2008) Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res 25:1751–1761PubMed CentralPubMedView ArticleGoogle Scholar
  32. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP et al (2013) Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309:1154–1162PubMedView ArticleGoogle Scholar
  33. Yang CL, Tsai PS, Huang CJ (2008) Effects of dexmedetomidine on regulating pulmonary inflammation in a rat model of ventilator-induced lung injury. Acta Anaesthesiol Taiwan 46:151–159PubMedView ArticleGoogle Scholar
  34. Wang J, Zhang H, Su C, Chen J, Zhu B, Zhang H et al (2014) Dexamethasone ameliorates H(2)S-induced acute lung injury by alleviating matrix metalloproteinase-2 and -9 expression. PLoS One 9:e94701PubMed CentralPubMedView ArticleGoogle Scholar
  35. Cussac D, Schaak S, Gales C, Flordellis C, Denis C, Paris H (2002) Alpha(2B)-adrenergic receptors activate MAPK and modulate proliferation of primary cultured proximal tubule cells. Am J Physiol Renal Physiol 282:F943–F952PubMedView ArticleGoogle Scholar
  36. Paris A, Mantz J, Tonner PH, Hein L, Brede M, Gressens P (2006) The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 102:456–461PubMedView ArticleGoogle Scholar

Copyright

© Chi et al. 2015

Advertisement

Journal of Translational Medicine

ISSN: 1479-5876

Contact us